- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------------------
FORM 8-K
-------------------------------
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
February 11, 1999 0-16132
- ------------------------------------------------ ----------------------
Date of Report (Date of earliest event reported) Commission File Number
CELGENE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 22-2711928
- ------------------------------ ---------------------------------------
State or other jurisdiction of (I.R.S. Employer Identification Number)
incorporation or organization)
7 Powder Horn Drive
Warren, New Jersey 07059
----------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(908) 271-1001
----------------------------------------------------
(Registrant's telephone number, including area code)
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
Item 5. Other Events.
On February 11, 1999, Celgene Corporation (the "Company") issued a
press release announcing its results for the fourth quarter and the full year
1998. Net revenue from continuing operations for the quarter was $2,665,000,
compared to $315,000 for the fourth quarter 1997. Fourth quarter 1998 revenue
consisted of research contract income of $430,000 and gross product sales of
THALOMID(TM) (thalidomide) of $2,441,000 ($2,235,000 after deductions). THALOMID
is the Company's first pharmaceutical product and was introduced to the market
in late September 1998. The net loss from continuing operations for the fourth
quarter 1998 was $8,375,000, or $0.51 per share, and in the comparable 1997
period the net loss was $8,211,000 or $0.59 per share.
The press release is filed as an exhibit hereto and is hereby
incorporated by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(a) not applicable
(b) not applicable
(c) Exhibits
99 Press Release, dated February 11, 1999.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: February 18, 1999 CELGENE CORPORATION
By: /s/John W. Jackson
---------------------------------------
Name: John W. Jackson
Title: Chairman of the Board and
Chief Executive Officer
3
EXHIBIT INDEX
Exhibit Description Page
- ---------- -------------------------------------------------------- ---------
99 Press Release, dated February 11, 1999.
4